metabolic-research
Research Use OnlyTirzepatide
Tirzepatide is a synthetic peptide that acts as a dual agonist at the GIP and GLP-1 receptors. Examined in pre-clinical and clinical literature for its dual-receptor mechanism and downstream effects on insulinotropic signaling. Sold for laboratory research and identification purposes only. Not for human consumption.
Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
Subscribe & save: $161
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
Research Overview
About Tirzepatide
Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism represents a paradigm shift from earlier single-receptor incretin therapies, with clinical evidence suggesting additive or synergistic metabolic effects that exceed what either pathway achieves independently.
The inclusion of GIP receptor agonism targets adipose tissue lipid metabolism, central appetite regulation through pathways distinct from GLP-1, and potentiation of insulin secretion through a separate intracellular signaling cascade. Phase 3 clinical data have reported mean body weight reductions of 15–22% in participants with obesity — positioning tirzepatide among the most effective pharmacological interventions studied for metabolic disease.
ROEHN supplies tirzepatide at 99% HPLC-verified purity as a lyophilized powder. Active research programs continue to explore applications beyond weight management, including non-alcoholic steatohepatitis (NASH), heart failure with preserved ejection fraction, and obstructive sleep apnea — reflecting the broad therapeutic potential of dual incretin receptor modulation.
